Shruti U. Gandhy

1.3k total citations
16 papers, 976 citations indexed

About

Shruti U. Gandhy is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Shruti U. Gandhy has authored 16 papers receiving a total of 976 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Shruti U. Gandhy's work include Cancer Immunotherapy and Biomarkers (6 papers), Prostate Cancer Treatment and Research (6 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). Shruti U. Gandhy is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Prostate Cancer Treatment and Research (6 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). Shruti U. Gandhy collaborates with scholars based in United States, Italy and New Zealand. Shruti U. Gandhy's co-authors include María Luisa Scattoni, Jacqueline N. Crawley, Laura Ricceri, Nathaniel Heintz, Kathryn K. Chadman, Shiaoching Gong, Kyounghyun Kim, Stephen Safe, Rhonda J. Rosengren and Lesley Larsen and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Clinical Cancer Research.

In The Last Decade

Shruti U. Gandhy

16 papers receiving 960 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shruti U. Gandhy United States 8 365 343 329 228 103 16 976
Satoko Ise Japan 7 211 0.6× 284 0.8× 242 0.7× 85 0.4× 28 0.3× 8 531
Natalia V. Malkova United States 11 250 0.7× 284 0.8× 155 0.5× 214 0.9× 49 0.5× 20 991
Cindy Skinner United States 25 907 2.5× 1.4k 4.1× 1.6k 4.9× 46 0.2× 28 0.3× 64 2.5k
Jin Nakatani Japan 12 334 0.9× 521 1.5× 509 1.5× 75 0.3× 13 0.1× 24 1.0k
Ralph Roeth Germany 11 253 0.7× 545 1.6× 573 1.7× 38 0.2× 6 0.1× 19 1.2k
Chang‐Lin Lu China 18 68 0.2× 242 0.7× 52 0.2× 153 0.7× 21 0.2× 38 716
Brian E. Eisinger United States 15 74 0.2× 241 0.7× 131 0.4× 143 0.6× 5 0.0× 19 753
Yuta Hara Japan 18 476 1.3× 288 0.8× 347 1.1× 149 0.7× 27 0.3× 38 1.1k
Noriyoshi Usui Japan 19 190 0.5× 508 1.5× 304 0.9× 52 0.2× 4 0.0× 41 1.1k
Korehito Yamanouchi Japan 22 56 0.2× 117 0.3× 303 0.9× 458 2.0× 13 0.1× 83 1.2k

Countries citing papers authored by Shruti U. Gandhy

Since Specialization
Citations

This map shows the geographic impact of Shruti U. Gandhy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shruti U. Gandhy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shruti U. Gandhy more than expected).

Fields of papers citing papers by Shruti U. Gandhy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shruti U. Gandhy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shruti U. Gandhy. The network helps show where Shruti U. Gandhy may publish in the future.

Co-authorship network of co-authors of Shruti U. Gandhy

This figure shows the co-authorship network connecting the top 25 collaborators of Shruti U. Gandhy. A scholar is included among the top collaborators of Shruti U. Gandhy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shruti U. Gandhy. Shruti U. Gandhy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Gandhy, Shruti U., Sandra J. Casak, Sirisha L. Mushti, et al.. (2023). FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements. Clinical Cancer Research. 29(20). 4027–4031. 11 indexed citations
2.
Gandhy, Shruti U., Fatima Karzai, Marijo Bilušić, et al.. (2023). Quantitative Analysis of Serial Positron Emission Tomography Imaging in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide. European Urology Oncology. 7(4). 735–741. 1 indexed citations
3.
Redman, Jason M., Benjamin A. Weinberg, Renee N. Donahue, et al.. (2022). A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer. The Oncologist. 27(3). 198–209. 30 indexed citations
4.
Madan, Ravi A., Renee N. Donahue, Fatima Karzai, et al.. (2022). 1412P Immune changes after enzalutamide (Enza) is added to androgen-deprivation therapy (ADT) in first-line metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 33. S1191–S1191. 1 indexed citations
5.
Atiq, Mohammad, Shruti U. Gandhy, Fatima Karzai, et al.. (2022). PSMA PET findings in patients with undetectable PSA more than 3 years after docetaxel for metastatic castration-sensitive prostate cancer (mCSPC).. Journal of Clinical Oncology. 40(16_suppl). e17046–e17046. 1 indexed citations
6.
Atiq, Mohammad, Shruti U. Gandhy, Fatima Karzai, et al.. (2021). Patients with undetectable PSA 2 years after docetaxel for metastatic castration sensitive prostate cancer (mCSPC).. Journal of Clinical Oncology. 39(15_suppl). e17044–e17044. 1 indexed citations
7.
Gandhy, Shruti U., Ravi A. Madan, & Jeanny B. Aragon‐Ching. (2020). The Immunotherapy Revolution in Genitourinary Malignancies. Immunotherapy. 12(11). 819–831. 9 indexed citations
8.
9.
Gandhy, Shruti U., Fatima Karzai, Jennifer L. Marté, et al.. (2020). PSA progression compared to radiographic or clinical progression in metastatic castration-resistant prostate cancer patients treated with enzalutamide.. Journal of Clinical Oncology. 38(6_suppl). 105–105. 6 indexed citations
10.
Sissung, Tristan M., Lisa M. Cordes, Cody J. Peer, et al.. (2020). Case Report: Severe Toxicity in an African–American Patient Receiving FOLFOX Carrying Uncommon Allelic Variants in DPYD. Pharmacogenomics. 22(2). 81–85. 5 indexed citations
11.
Gandhy, Shruti U., Parisa Imanirad, Un-Ho Jin, et al.. (2015). Specificity protein (Sp) transcription factors and metformin regulate expression of the long non-coding RNA HULC. Oncotarget. 6(28). 26359–26372. 26 indexed citations
12.
Zou, Yaqun, Daniela Zwolanek, Yanjia Hu, et al.. (2013). O.2 Collagen type XII: A new congenital matrix and muscle disease. Neuromuscular Disorders. 23(9-10). 739–740. 1 indexed citations
13.
Gandhy, Shruti U., Kyounghyun Kim, Lesley Larsen, Rhonda J. Rosengren, & Stephen Safe. (2012). Curcumin and synthetic analogs induce reactive oxygen species and decreases specificity protein (Sp) transcription factors by targeting microRNAs. BMC Cancer. 12(1). 564–564. 134 indexed citations
14.
Moon, Jisook, May Chen, Shruti U. Gandhy, et al.. (2010). Perinatal choline supplementation improves cognitive functioning and emotion regulation in the Ts65Dn mouse model of Down syndrome.. Behavioral Neuroscience. 124(3). 346–361. 105 indexed citations
15.
Chadman, Kathryn K., Shiaoching Gong, María Luisa Scattoni, et al.. (2008). Minimal aberrant behavioral phenotypes of neuroligin‐3 R451C knockin mice. Autism Research. 1(3). 147–158. 229 indexed citations
16.
Scattoni, María Luisa, Shruti U. Gandhy, Laura Ricceri, & Jacqueline N. Crawley. (2008). Unusual Repertoire of Vocalizations in the BTBR T+tf/J Mouse Model of Autism. PLoS ONE. 3(8). e3067–e3067. 415 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Satoko Ise Breakdown of academic impact, for papers by Natalia V. Malkova Breakdown of academic impact, for papers by Cindy Skinner Breakdown of academic impact, for papers by Jin Nakatani Breakdown of academic impact, for papers by Ralph Roeth Breakdown of academic impact, for papers by Chang‐Lin Lu Breakdown of academic impact, for papers by Brian E. Eisinger Breakdown of academic impact, for papers by Yuta Hara Breakdown of academic impact, for papers by Noriyoshi Usui Breakdown of academic impact, for papers by Korehito Yamanouchi
Rankless by CCL
2026